Abstract
The effect of a recently developed oxytocin antagonist dTVT, i.e. deamino-[2-D-tyrosine(OEt)-4-threonine-8-ornithine] oxytocin on uterine contraction of pregnant rats was studied in vitro. The following results were obtained. 1. dTVT treatment did not affect spontaneous PGE2- or PGF2 alpha-stimulated contraction, while it slightly suppressed PGE1 analogue (Gemeprost)-stimulated contraction of the uterus. 2. Following treatment with dTVT (5-50 micrograms/ml), oxytocin-stimulated uterine contraction was gradually and slowly suppressed, resulting in an attenuation curve. Ritodrine treatment, on the other hand, rapidly suppressed spontaneous uterine contraction as well as contraction stimulated by various oxytocics. Suppression of oxytocin-stimulated uterine contraction by dTVT took much longer (14.8 +/- 1.1 min) to take effect than that by ritodrine (less than 1 min).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Asia-Oceania Journal of Obstetrics and Gynaecology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
